Capricor Revenue and Competitors
Estimated Revenue & Valuation
- Capricor's estimated annual revenue is currently $20.3M per year.
- Capricor's estimated revenue per employee is $155,000
Employee Data
- Capricor has 131 Employees.
- Capricor grew their employee count by 32% last year.
Capricor's People
Name | Title | Email/Phone |
---|---|---|
1 | CEO | Reveal Email/Phone |
2 | EVP, General Counsel | Reveal Email/Phone |
3 | VP, Head Research & Product Development | Reveal Email/Phone |
4 | VP Quality | Reveal Email/Phone |
5 | VP Clinical Operations | Reveal Email/Phone |
6 | VP Program Management and Business Operations | Reveal Email/Phone |
7 | VP Research and Development | Reveal Email/Phone |
8 | VP Clinical Development | Reveal Email/Phone |
9 | VP Quality | Reveal Email/Phone |
10 | Chief Financial Officer | Reveal Email/Phone |
Capricor Competitors & AlternativesAdd Company
Competitor Name | Revenue | Number of Employees | Employee Growth | Total Funding | Valuation |
---|---|---|---|---|---|
#1 | $63.2M | 252 | 35% | N/A | N/A |
#2 | $1.2M | 14 | N/A | N/A | N/A |
#3 | $25.3M | 101 | -9% | N/A | N/A |
What Is Capricor?
Capricor Therapeutics, Inc. (NASDAQ: CAPR) is a clinical-stage biotechnology company focused on the development of cell and exosome-based therapeutics for the treatment and prevention of serious diseases. Capricor's lead candidate, CAP-1002, is an allogeneic cell therapy that is currently in clinical development for the treatment of Duchenne muscular dystrophy and complications associated with COVID-19. Capricor is also investigating the field of exosomes and are exploring the potential of exosome-based candidates to treat or prevent a variety of disorders. Our innovative technology builds upon a large body of scientific research and enables us to approach the treatment of diseases in novel ways. Capricor's lead candidate, CAP-1002, is an allogeneic cardiac cell therapy. CAP-1002 consists of cardiosphere-derived cells, or CDCs, a unique population of cells which include progenitor cells that have been shown to exert potent immunomodulatory activity, which alters the immune system's activity to stimulate cellular regeneration. CDCs have been the subject of over 100 peer-reviewed scientific publications and have been administered to over 200 human subjects across several clinical trials. Capricor has also established itself as one of the leading companies investigating the field of exosome science. Exosomes are nanosized particles with biologically-active contents that are secreted by cells and serve to direct or re-direct the activities of other cells and are emerging as an exciting class of potential therapeutic agents. We are now focused on developing a precision-engineered exosome platform technology that can carry defined sets of effector molecules including nucleic acids which exert their effects through defined mechanisms of action. We have begun work on our expansion of our exosome platform technology that potentially may be used for vaccine development, vesicle-mediated protein therapies and treatment of inherited diseases.
keywords:N/AN/A
Total Funding
131
Number of Employees
$20.3M
Revenue (est)
32%
Employee Growth %
N/A
Valuation
N/A
Accelerator
Capricor News
Capricor is currently developing CAP-1002 for the treatment of Duchenne muscular dystrophy, a rare, fatal neuromuscular genetic disease, and...
A phase 2 trial of Capricor Therapeutics' (CAPR -24.8%) COVID-19 treatment CAP-1002 met its primary objective of safety.
-Primary Objective of Study Met: CAP-1002 was Safe and Well Tolerated-. SAN DIEGO, March 28, 2022 (GLOBE NEWSWIRE) -- Capricor Therapeutics...
Company Name | Revenue | Number of Employees | Employee Growth | Total Funding |
---|---|---|---|---|
#1 | $23.6M | 131 | -1% | N/A |
#2 | $17M | 131 | -8% | $20.4M |
#3 | $27.5M | 131 | -9% | N/A |
#4 | $26.9M | 131 | -1% | $79.8M |
#5 | $32.9M | 131 | 8% | N/A |